Lidocaine Aguettant (Lidocaine Hydrochloride)

Lidocaine works by blocking voltage‑gated sodium channels on nerve membranes, which prevents the influx of sodium ions needed for depolarisation. This inhibition stops the generation and propagation of action potentials, resulting in a reversible loss of sensation in the area where the drug is applied.

The dose of Lidocaine Aguettant is determined by the prescribing clinician based on the specific procedure, patient weight, and clinical context. Healthcare professionals calculate the amount needed to achieve adequate local anesthesia while staying within established safety limits for lidocaine exposure.

Safety data for Lidocaine Aguettant in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Clinicians are advised to assess each case individually and consider alternative options when possible.

To order Lidocaine Aguettant, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset and moderate duration, making it suitable for short‑ to medium‑length airway procedures. Compared with agents such as bupivacaine, lidocaine has a shorter half‑life and lower cardiotoxic potential, but may require repeat dosing for longer surgeries.

Lidocaine Aguettant should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture. Ensure that the container is sealed when not in use and that any unused portion is discarded according to local regulations after the labeled expiry date.

The product is administered by a qualified healthcare professional via endotracheopulmonary routes, typically as a topical spray or instillation onto the mucosal surfaces of the airway. The exact technique depends on the procedure, and the drug should be applied only to the intended area to achieve localized anesthesia.

Serious risks include systemic toxicity leading to cardiac arrhythmias, seizures, severe allergic reactions (anaphylaxis), and rare cases of methemoglobinemia. Early signs of toxicity such as dizziness, tinnitus, or altered mental status should prompt immediate medical evaluation and supportive care.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid the product. It is also contraindicated in individuals with significant cardiac conduction disorders, severe liver dysfunction, or those taking medications that markedly increase lidocaine plasma levels without appropriate monitoring.